The goal of this clinical trial is to evaluate the feasibility, safety and effectiveness of radiotherapy with fewer days of treatment and a higher dose of radiation each day in patients under 70 years of age diagnosed with a brain tumor known as glioblastoma.
The goal of this clinical trial is to evaluate the feasibility (accrual of patients, planning of radiotherapy), safety (acute and late neurological toxicity) and effectiveness (overall survival and progression free survival) of radiotherapy with fewer days of treatment and a higher dose of radiation each day (dose of 60 Gy in 20 fractions of 3 Gy) in patients between 18 and 70 years of age diagnosed with a brain tumor known as glioblastoma. Additionally, circulating tumor cells will be searched in the blood before and after radiotherapy and its quantitative and qualitative analysis will be correlated with the survival outcomes.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
60 Gy in 20 fractions of 3 Gy
Feasibility of accrual and planning
Accrual of patients, timely and adequated planning of radiotherapy
Time frame: From enrollment to the end of planning of the 10 patients at 5 months
Incidence of acute and late neurological toxicity
Incidence of headache, brain edema and brain radionecrosis will be classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: Weekly evaluation during treatment and at 4, 12, 24, 36 weeks in the first year and every 6 months until 3 years after radiotherapy.
Overall Survival and Progression Free Survival
Death from any cause and disease progression during treatment and follow-up time
Time frame: Start of radiotherapy to the date of event (death or progression of disease) up tp 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.